Athenex: Drops as FDA declines to approve breast cancer treatment application

Athenex

01/03/2021 12:41

** Shares of drugmaker  ATNX.O  fall 55.3% to $5.40
premarket
    ** Co says U.S. FDA declines to approve new drug application
(NDA) for co's treatment for metastatic breast cancer
 urn:newsml:reuters.com:*:nGNX7hXnMr
    ** Says FDA indicated concern regarding a safety risk as
well as uncertainty over results of main goal of the study
    ** FDA asks co to conduct new clinical trial in a patient
population with metastatic breast cancer representative of U.S.
population 
    ** Co plans meeting with FDA on design and scope of clinical
trial 
    ** Up to last close, ATNX stock up 9.4% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))